Onvia Inc. (NASDAQ:ONVI) shares remains unchanged in last trading session and ended the day at $4.09. ONVI Gross Margin is 84.90% and its has a return on assets of -5.30%. Onvia Inc. (NASDAQ:ONVI) quarterly performance is -5.54%.
American Campus Communities, Inc. (NYSE:ACC) ended the last trading day at $37.82. Company weekly volatility is calculated as 1.39% and price to cash ratio as 482.72. American Campus Communities, Inc. (NYSE:ACC) showed a weekly performance of 1.75%.
Bill Bayless, CEO of American Campus Communities (NYSE:ACC) was inducted into the West Virginia University College of Business and Economics Roll of Distinguished Alumni on Friday, October 9th.
On 12 October, Marcus & Millichap, Inc. (NYSE:MMI) shares fell -0.83% and was closed at $47.99. Marcus & Millichap, Inc. (NYSE:MMI) year to date (YTD) performance is 44.33%.
On 7 October, it was reported Institutional Property Advisors (IPA), a division of Marcus & Millichap Inc. (NYSE:MMI) specializing in serving institutional and major private real estate investors, announced the sale of Promenade Terrace, a 330-unit apartment community located in Corona, Calif. near the Orange County border. The $78.5 million sales price equates to nearly $238,000 per unit.
VIVUS Inc. (NASDAQ:VVUS) shares fell -13.00% in last trading session and ended the day at $1.74. VVUS Gross Margin is 67.00% and its has a return on assets of -29.80%. VIVUS Inc. (NASDAQ:VVUS) quarterly performance is -25.00%.
On September 30, 2015, the Board of Directors of VIVUS, Inc., (NASDAQ:VVUS) or the Company, appointed Johann Noor Mohamed, the Company’s Vice President and Corporate Controller, to serve as the Company’s interim Chief Financial Officer and interim Chief Accounting Officer effective October 1, 2015.
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) caters to the Healthcare space. Its weekly performance is -1.65%. On the last day of trading company shares ended up at $4.17. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) distance from 50-day simple moving average (SMA50) is -3.05%.
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that abstracts for two posters addressing preclinical results with the company’s pan-caspase inhibitors, have been accepted for presentation at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco November 13-17, 2015.
Leave a Reply